Metabolic dysfunction-associated liver disease

7 clinical trials

Quick filters

Clinical trials for Metabolic dysfunction-associated liver disease

7 trials across Europe

See all trials →

Quick filters

7 Clinical trials

Metabolic dysfunction-associated liver disease

Recruiting

Investigational

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Bio89-100
Sponsor:89bio Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Ly3437943 Sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Glucose tolerance impaired+1

Recruiting

Registered drugNo placebo

Study of Pioglitazone and Metformin combination treatment for patients with Metabolic Associated Fatty Liver Disease and prediabetes

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pioglitazone
Sponsor:Consorcio Centro De Investigacion Biomedica En Red

Contact Research Centre

Metabolic dysfunction-associated liver disease+2

Not recruiting

Registered drug

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Opella Healthcare Group S.A.S.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Not recruiting

Investigational

Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Investigational

Belgium

Participants:18–64 years
Substances:Gsk4532990A
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+3

Not recruiting

Registered drugNo placebo

Study on the Effects of Semaglutide on Insulin Resistance and Lipid Metabolism in Women with Obesity and Non-Alcoholic Fatty Liver Disease

Registered drugNo placebo

Denmark

Participants:18–64 years
Substances:Semaglutide
Sponsor:Region Midtjylland

Contact Research Centre

See all trials →

Metabolic dysfunction-associated liver disease

Clinical trials for Metabolic dysfunction-associated liver disease

Metabolic dysfunction-associated liver disease

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Metabolic dysfunction-associated liver disease

Glucose tolerance impaired+1

Study of Pioglitazone and Metformin combination treatment for patients with Metabolic Associated Fatty Liver Disease and prediabetes

Metabolic dysfunction-associated liver disease+2

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Metabolic dysfunction-associated liver disease

Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Metabolic dysfunction-associated steatohepatitis+3

Study on the Effects of Semaglutide on Insulin Resistance and Lipid Metabolism in Women with Obesity and Non-Alcoholic Fatty Liver Disease

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.